Experienced in Virilizing Ovarian Tumor

Dr. Vincent M. Chung

Hematology | Oncology | Hematology Oncology
City Of Hope Medical Foundation
209 Fair Oaks Ave, 
South Pasadena, CA 
Clinical Trials:Currently Recruiting for 3 Trials
Offers Telehealth
Experienced in Virilizing Ovarian Tumor
City Of Hope Medical Foundation
209 Fair Oaks Ave, 
South Pasadena, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Vincent Chung is a Hematologist and an Oncologist in South Pasadena, California. Dr. Chung is rated as an Experienced provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Pancreatic Cancer, Familial Pancreatic Cancer, Cholangiocarcinoma (Bile Duct Cancer), Endoscopy, and Gastrostomy.

His clinical research consists of co-authoring 96 peer reviewed articles and participating in 23 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Hematology Oncology
Licenses
Internal Medicine in CA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Inland Empire Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

CITY OF HOPE MEDICAL FOUNDATION
209 Fair Oaks Ave, South Pasadena, CA 91030
Other Locations
CITY OF HOPE MEDICAL FOUNDATION
1500 Duarte Rd, Duarte, CA 91010
CITY OF HOPE MEDICAL FOUNDATION
1500 E Duarte Rd, Duarte, CA 91010

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

23 Clinical Trials

First in Human Phase 1 Study of AOH1996 in Patients With Refractory Solid Tumors
First in Human Phase 1 Study of AOH1996 in Patients With Refractory Solid Tumors
Enrollment Status: Recruiting
Publish Date: September 18, 2025
Intervention Type: Drug
Study Phase: Phase 1
NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies
NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies
Enrollment Status: Recruiting
Publish Date: September 05, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects With Solid Tumors or Lymphoma
An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects With Solid Tumors or Lymphoma
Enrollment Status: Recruiting
Publish Date: June 24, 2025
Intervention Type: Drug
Study Drug: VMD-928
Study Phase: Phase 1
Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients With Germline BRCA1 or BRCA2 Mutations
Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients With Germline BRCA1 or BRCA2 Mutations
Enrollment Status: Suspended
Publish Date: October 07, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Olaparib, Pembrolizumab
Study Phase: Phase 2
A Phase 1 Study Evaluating Safety, Tolerability, and Preliminary Antitumor Activity of Entinostat and Nivolumab With or Without Ipilimumab in Advanced Solid Tumors
A Phase 1 Study Evaluating Safety, Tolerability, and Preliminary Antitumor Activity of Entinostat and Nivolumab With or Without Ipilimumab in Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: October 02, 2025
Intervention Type: Procedure, Other, Drug, Biological
Study Drugs: Entinostat, Ipilimumab, Nivolumab
Study Phase: Phase 1
Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer
Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug, Other
Study Drugs: Fluorouracil, Irinotecan Hydrochloride, Leucovorin Calcium, Veliparib
Study Phase: Phase 2
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
A Phase II Investigator Sponsored Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers
A Phase II Investigator Sponsored Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers
Enrollment Status: Completed
Publish Date: September 22, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Phase I Study of Anetumab Ravtansine in Combination With Either Anti-PD-1 Antibody, or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma
A Phase I Study of Anetumab Ravtansine in Combination With Either Anti-PD-1 Antibody, or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: September 15, 2025
Intervention Type: Biological, Procedure, Drug
Study Drugs: Anetumab ravtansine, Gemcitabine hydrochloride, Ipilimumab, Nivolumab
Study Phase: Phase 1
First in Human Phase 1 Trial of ELI-002 Immunotherapy as Treatment for Subjects With Kirsten Rat Sarcoma (KRAS) Mutated Pancreatic Ductal Adenocarcinoma and Other Solid Tumors
First in Human Phase 1 Trial of ELI-002 Immunotherapy as Treatment for Subjects With Kirsten Rat Sarcoma (KRAS) Mutated Pancreatic Ductal Adenocarcinoma and Other Solid Tumors
Enrollment Status: Completed
Publish Date: September 05, 2025
Intervention Type: Drug
Study Drug: ELI-002 Amph-CpG-7909
Study Phase: Phase 1
First-in-Human, Dose Finding, Open Label Phase 1A-1B Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies
First-in-Human, Dose Finding, Open Label Phase 1A-1B Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies
Enrollment Status: Completed
Publish Date: July 20, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
Enrollment Status: Completed
Publish Date: June 11, 2025
Intervention Type: Drug
Study Drugs: Cisplatin, Gemcitabine, Nab-Paclitaxel
Study Phase: Phase 3
A Pilot Study of Gemcitabine, Abraxane, Metformin and a Standardized Dietary Supplement (DS) in Patients With Unresectable Pancreatic Cancer
A Pilot Study of Gemcitabine, Abraxane, Metformin and a Standardized Dietary Supplement (DS) in Patients With Unresectable Pancreatic Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 20, 2025
Intervention Type: Other, Drug, Dietary supplement
Study Drugs: Gemcitabine, Paclitaxel, Metformin
Study Phase: Phase 1
A Phase I Study of a p53MVA Vaccine in Combination With Pembrolizumab
A Phase I Study of a p53MVA Vaccine in Combination With Pembrolizumab
Enrollment Status: Active_not_recruiting
Publish Date: March 20, 2025
Intervention Type: Biological, Other
Study Drugs: Modified Vaccinia Virus Ankara Vaccine Expressing p53, Pembrolizumab
Study Phase: Phase 1
An Open-label, Dose Escalation and Expansion, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of TAK-500, a Novel Stimulator of Interferon Genes Agonist, as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Select Locally Advanced or Metastatic Solid Tumors
An Open-label, Dose Escalation and Expansion, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of TAK-500, a Novel Stimulator of Interferon Genes Agonist, as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Select Locally Advanced or Metastatic Solid Tumors
Enrollment Status: Terminated
Publish Date: March 07, 2025
Intervention Type: Drug
Study Drugs: TAK-500, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Enrollment Status: Completed
Publish Date: February 13, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Randomized Phase 2/3 Multi-Center Study of SM-88 in Subjects With Pancreatic Cancer Whose Disease Has Progressed or Recurred
A Randomized Phase 2/3 Multi-Center Study of SM-88 in Subjects With Pancreatic Cancer Whose Disease Has Progressed or Recurred
Enrollment Status: Terminated
Publish Date: November 06, 2024
Intervention Type: Drug
Study Drugs: SM-88, MPS (methoxsalen, phenytoin, sirolimus), Capecitabine, Gemcitabine, 5-FU
Study Phase: Phase 2/Phase 3
A Phase 1, Open-Label, Dose-Escalation, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors
A Phase 1, Open-Label, Dose-Escalation, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: August 09, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Randomized Phase 2 Study of Atezolizumab in Combination With Cobimetinib Versus Atezolizumab Monotherapy in Participants With Unresectable Cholangiocarcinoma
A Randomized Phase 2 Study of Atezolizumab in Combination With Cobimetinib Versus Atezolizumab Monotherapy in Participants With Unresectable Cholangiocarcinoma
Enrollment Status: Completed
Publish Date: April 05, 2024
Intervention Type: Procedure, Drug
Study Drugs: Atezolizumab, Cobimetinib
Study Phase: Phase 2
S1313, A Phase IB/II Randomized Study of Modified FOLFIRINOX + Pegylated Recombinant Human Hyaluronidase (PEGPH20) Versus Modified FOLFIRINOX Alone in Patients With Good Performance Status Metastatic Pancreatic Adenocarcinoma
S1313, A Phase IB/II Randomized Study of Modified FOLFIRINOX + Pegylated Recombinant Human Hyaluronidase (PEGPH20) Versus Modified FOLFIRINOX Alone in Patients With Good Performance Status Metastatic Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: February 09, 2024
Intervention Type: Drug
Study Drugs: PEGPH20, Oxaliplatin, Leucovorin, Irinotecan, 5-fluorouracil
Study Phase: Phase 1/Phase 2
A Phase III Multicenter Open-label Randomized Trial to Evaluate Efficacy and Safety of Folfirinox (FFX) Versus Combination of CPI-613 With Modified Folfirinox (mFFX) in Patients With Metastatic Adenocarcinoma of the Pancreas
A Phase III Multicenter Open-label Randomized Trial to Evaluate Efficacy and Safety of Folfirinox (FFX) Versus Combination of CPI-613 With Modified Folfirinox (mFFX) in Patients With Metastatic Adenocarcinoma of the Pancreas
Enrollment Status: Completed
Publish Date: January 03, 2023
Intervention Type: Drug
Study Drugs: CPI 613, mFolfirinox, Folfirinox
Study Phase: Phase 3
A SU2C Catalyst ® Randomized Phase II Trial of the PD1 Inhibitor Pembrolizumab With or Without a Vitamin D Receptor Agonist Paricalcitol in Patients With Stage IV Pancreatic Cancer Who Have Been Placed in Best Possible Response
A SU2C Catalyst ® Randomized Phase II Trial of the PD1 Inhibitor Pembrolizumab With or Without a Vitamin D Receptor Agonist Paricalcitol in Patients With Stage IV Pancreatic Cancer Who Have Been Placed in Best Possible Response
Enrollment Status: Completed
Publish Date: December 27, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1B, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
A Phase 1B, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
Enrollment Status: Terminated
Publish Date: February 07, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 20 Less Clinical Trials

96 Total Publications

Pancreatic Cancer Immunotherapy: A Team-Based Approach.
Pancreatic Cancer Immunotherapy: A Team-Based Approach.
Journal: Cancer treatment and research
Published: August 23, 2025
Similar Doctors
Distinguished in Virilizing Ovarian Tumor
Dr. Daphne B. Stewart
Oncology | Hematology | Hematology Oncology
Distinguished in Virilizing Ovarian Tumor
Dr. Daphne B. Stewart
Oncology | Hematology | Hematology Oncology

USC Care Medical Group Inc

1520 San Pablo St, Fl 4, 
Los Angeles, CA 
 (5.1 miles away)
800-872-2273
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Daphne Stewart is an Oncologist and a Hematologist in Los Angeles, California. Dr. Stewart is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. Her top areas of expertise are Ovarian Cancer, Breast Cancer, Ovarian Carcinosarcoma, Virilizing Ovarian Tumor, and Gastrostomy.

Distinguished in Virilizing Ovarian Tumor
Dr. Gottfried E. Konecny
Hematology Oncology | Hematology | Oncology
Distinguished in Virilizing Ovarian Tumor
Dr. Gottfried E. Konecny
Hematology Oncology | Hematology | Oncology

The Regents Of The University Of California

200 Ucla Medical Plz, Suite 165 34, 
Los Angeles, CA 
 (17.4 miles away)
310-824-8403
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Gottfried Konecny is a Hematologist Oncology specialist and a Hematologist in Los Angeles, California. Dr. Konecny is rated as an Elite provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Ovarian Cancer, Endometrial Cancer, Virilizing Ovarian Tumor, and Ovarian Carcinosarcoma.

Distinguished in Virilizing Ovarian Tumor
Dr. Mihaela C. Cristea
Oncology
Distinguished in Virilizing Ovarian Tumor
Dr. Mihaela C. Cristea
Oncology
1500 E Duarte Rd, 
Duarte, CA 
 (10.1 miles away)
626-359-8111
Languages Spoken:
English
See accepted insurances

Mihaela Cristea is an Oncologist in Duarte, California. Dr. Cristea is rated as an Elite provider by MediFind in the treatment of Virilizing Ovarian Tumor. Her top areas of expertise are Ovarian Cancer, Endometrial Cancer, Lung Cancer, Virilizing Ovarian Tumor, and Endoscopy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Chung's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 20 Advanced Conditions
View All 77 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile